Skip to content
MS
rate-limiting unreviewed

Galactose-1-phosphate uridylyltransferase (GALT)

1 reactions · 1 pathways

Clinical / pharmacological. Classic galactosaemia: cataracts, jaundice, E. coli sepsis, intellectual disability

What it does, reaction by reaction

1 reactions

Galactose Metabolism Carbohydrate Metabolism · Cytosol

step 4 Reversible

Galactose-1-phosphate + UDP-glucose → glucose-1-phosphate + UDP-galactose

Converts Galactose-1-phosphate UDP-glucose into Glucose-1-phosphate UDP-galactose

Notes

Galactose-1-phosphate uridylyltransferase (GALT) exchanges uridyl groups. This central Leloir reaction requires the activated-sugar substrate UDP-glucose; it is reversible, but physiologic flux is directed toward glucose-1-phosphate formation. It is the critical/committed processing step for galactose-1-phosphate.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Galactose Metabolism

Listed there as: Galactose-1-phosphate uridylyltransferase

Accelerated by

Galactose-1-phosphate and UDP-glucose availability

Inhibited by

Product accumulation; inherited loss causes substrate trapping

Hormonal control

No major acute hormonal control

Recent literature

Europe PMC · from cache · sorted by publication date

  1. 1
  2. 2
    Recent advances and clinical relevance of microbiome dynamics in health and disease.

    Gavanji S, Suhail M, Bencurova E, Dandekar T, Othman EM. · 2026-06-12

    open access unreviewed
  3. 3
    Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.

    Soroush Fard A, Kalantar K, Teimoori A, Barati M, Arezumand R, Fani M. · 2026-06-11

    open access unreviewed
  4. 4
    Repurposing the antispasmodic drug pinaverium bromide as a novel antifungal agent and synergist against <i>Candida albicans</i>.

    Yao J, Yang Z, Hang X, Chen T, Li B, Shi T, Quan K, Xu J, Zeng L, Feng G, Bi H. · 2026-06-01

    open access unreviewed
  5. 5
    The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.

    Ding JB, Lin MX, Zang D, Chen J. · 2026-05-28

    open access unreviewed
  6. 6
    Immune discrimination between commensals and pathogenic bacteria.

    Alanazi HH. · 2026-05-22

    open access unreviewed
  7. 7
  8. 8
    Targeting the gut-kidney axis to improve kidney transplantation prognosis: from mechanisms to clinical intervention strategies.

    Cao H, Sun J, Lv Y, Ye J, Wang Y, Jiang H. · 2026-03-17

    cited 1× open access unreviewed
  9. 9
    Mislocalisation of FLT3-ITD receptor contributes to MV4-11 leukaemia cell resistance to antibody-drug conjugate.

    Nirachonkul W, Farrell MP, Tolbert TJ, Okonogi S, Tima S, Anuchapreeda S, Chiampanichayakul S, Siahaan TJ. · 2026-03-05

    open access unreviewed
  10. 10
    Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.

    Benedé-Ubieto R, Estévez-Vázquez O, Acar R, Leal-Lassalle H, Gutierrez AH, Redondo-Urzainqui A, Iborra S, Odi… · 2026-02-21

    cited 2× open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.